OOIR: Observatory of International Research

Papers

(The TQCC of Cytokine & Growth Factor Reviews is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-10-01 to 2024-10-01.)

Article	Citations
SARS-CoV-2 Mutations and their Viral Variants	120
The NLRP3 inflammasome and COVID-19: Activation, pathogenesis and therapeutic strategies	103
The cytokine storm in COVID-19: Further advances in our understanding the role of specific chemokines involved	92
Crosstalk between glucose metabolism, lactate production and immune response modulation	90
Hallmarks of aging and immunosenescence: Connecting the dots	86
SARS-CoV-2 mediated neuroinflammation and the impact of COVID-19 in neurological disorders	84
Applications of the regenerative capacity of platelets in modern medicine	74
Mechanisms of NLRP3 priming in inflammaging and age related diseases	73
Correlation between PD-1/PD-L1 expression and polarization in tumor-associated macrophages: A key player in tumor immunotherapy	64
Is Toll-like receptor 4 involved in the severity of COVID-19 pathology in patients with cardiometabolic comorbidities?	59
Semaphorins in health and disease	54
Pathophysiological role of growth differentiation factor 15 (GDF15) in obesity, cancer, and cachexia	53
Crosstalk between ferroptosis and the epithelial-mesenchymal transition: Implications for inflammation and cancer therapy	53
SARS-CoV-2 infection and oxidative stress: Pathophysiological insight into thrombosis and therapeutic opportunities	50
Receptor binding competition: A paradigm for regulating TGF-β family action	50
S100A8/A9 in COVID-19 pathogenesis: Impact on clinical outcomes	48
The involvement of TH17 cells in the pathogenesis of IBD	48
ALCAM/CD166: A pleiotropic mediator of cell adhesion, stemness and cancer progression	48
FGF/FGFR signaling: From lung development to respiratory diseases	48
Scarless wound healing: Current insights from the perspectives of TGF-β, KGF-1, and KGF-2	47
Growth differentiation factor-15 and its role in diabetes and cardiovascular disease	47
Chemokine networks modulating natural killer cell trafficking to solid tumors	46
The evolving epidemiology of monkeypox virus	45
Recent advances in the treatment of IBD: Targets, mechanisms and related therapies	45
SARS-CoV-2: Targeted managements and vaccine development	44

Secretory Leukocyte Protease Inhibitor (SLPI) in mucosal tissues: Protects against inflammation, but promotes cancer	43
The RNA binding protein SRSF1 is a master switch of gene expression and regulation in the immune system	42
Cytokines in oncolytic virotherapy	41
Antiphospholipid antibodies and risk of post-COVID-19 vaccination thrombophilia: The straw that breaks the camel's back?	40
Biological functions of NLRP3 inflammasome: A therapeutic target in inflammatory bowel disease	40
Engineering and combining oncolytic measles virus for cancer therapy	40
Biological functions and therapeutic opportunities of soluble cytokine receptors	39
Granulocyte macrophage colony-stimulating factor has come of age: From a vaccine adjuvant to antiviral immunotherapy	39
An evaluation of the effects of probiotics on tumoral necrosis factor (TNF-α) signaling and gene expression	38
The determinant role of IL-6 in the establishment of inflammation leading to spontaneous preterm birth	38
IL-36 in chronic inflammation and cancer	38
The immunosuppressive and pro-tumor functions of CCL18 at the tumor microenvironment	36
Revisiting IRF1-mediated antiviral innate immunity	36
Pro-angiogenic activity and vasculogenic mimicry in the tumor microenvironment by leptin in cancer	35
Mechanisms of measles virus oncolytic immunotherapy	35
Selective inhibition of Tumor necrosis factor receptor-1 (TNFR1) for the treatment of autoimmune diseases	35
Cancer-associated fibroblasts: Vital suppressors of the immune response in the tumor microenvironment	34
Asprosin, a novel pleiotropic adipokine implicated in fasting and obesity-related cardio-metabolic disease: Comprehensive review of preclinical and clinical evidence	34
Glycogen synthase kinase-3: A putative target to combat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic	32
Exercise tolls the bell for key mediators of low-grade inflammation in dysmetabolic conditions	32
The Coronavirus pandemic – 2022: Viruses, variants & vaccines	32
MDSCs in sepsis-induced immunosuppression and its potential therapeutic targets	31
Galectins as modulators of receptor tyrosine kinases signaling in health and disease	31
Principles of the activin receptor signaling pathway and its inhibition	30
Role of SARS-CoV-2 -induced cytokines and growth factors in coagulopathy and thromboembolism	29
The interleukin-1 cytokine family members: Role in cancer pathogenesis and potential therapeutic applications in cancer immunotherapy	28
Development of mRNA vaccines against respiratory syncytial virus (RSV)	28
The cytokine interleukin-11 crucially links bone formation, remodeling and resorption	27
Pathogenic mechanisms of glucocorticoid-induced osteoporosis	27
Multifactorial effects of hyperglycaemia, hyperinsulinemia and inflammation on bone remodelling in type 2 diabetes mellitus	26
Small extracellular vesicle-mediated bidirectional crosstalk between neutrophils and tumor cells	26
Crosstalk between lncRNAs in the apoptotic pathway and therapeutic targets in cancer	26
Immune evasion of neutralizing antibodies by SARS-CoV-2 Omicron	25
Macrophage-derived cytokines in pneumonia: Linking cellular immunology and genetics	24
The IL-2A receptor pathway and its role in lymphocyte differentiation and function	23
Covid-19 in Brazil: A sad scenario	23
Chagas disease: Immunology of the disease at a glance	22
The two-faces of NK cells in oncolytic virotherapy	22
IL-6 and its role in IgA nephropathy development	22
Intracellular partners of fibroblast growth factors 1 and 2 - implications for functions	22
Netrin-1: An emerging player in inflammatory diseases	21
The pros and cons of interferons for oncolytic virotherapy	21
COVID-19 as a mediator of interferon deficiency and hyperinflammation: Rationale for the use of JAK1/2 inhibitors in combination with interferon	21
Emerging mechanisms and applications of low-dose IL-2 therapy in autoimmunity	21